Single User License
INR 136340
Site License
INR 272680
Corporate User License
INR 409020

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


General Anxiety Disorder-Pipeline Review, H1 2015

General Anxiety Disorder-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

General Anxiety Disorder-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'General Anxiety Disorder-Pipeline Review, H1 2015', provides an overview of the General Anxiety Disorder's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for General Anxiety Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for General Anxiety Disorder and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of General Anxiety Disorder

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for General Anxiety Disorder and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the General Anxiety Disorder products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the General Anxiety Disorder pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for General Anxiety Disorder

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding General Anxiety Disorder pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

General Anxiety Disorder Overview 6

Therapeutics Development 7

Pipeline Products for General Anxiety Disorder-Overview 7

Pipeline Products for General Anxiety Disorder-Comparative Analysis 8

General Anxiety Disorder-Therapeutics under Development by Companies 9

General Anxiety Disorder-Pipeline Products Glance 10

Late Stage Products 10

Clinical Stage Products 11

Early Stage Products 12

Unknown Stage Products 13

General Anxiety Disorder-Products under Development by Companies 14

General Anxiety Disorder-Companies Involved in Therapeutics Development 15

Edgemont Pharmaceuticals, LLC 15

H. Lundbeck A/S 16

Pfizer Inc. 17

General Anxiety Disorder-Therapeutics Assessment 18

Assessment by Monotherapy Products 18

Assessment by Target 19

Assessment by Mechanism of Action 21

Assessment by Route of Administration 23

Assessment by Molecule Type 24

Drug Profiles 25

EDG-008-Drug Profile 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

lorazepam ER-Drug Profile 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

PF-06372865-Drug Profile 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

Small Molecule to Modulate Glutamate Receptor for Anxiety Disorders-Drug Profile 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

tedatioxetine-Drug Profile 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

vortioxetine hydrobromide-Drug Profile 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

General Anxiety Disorder-Recent Pipeline Updates 35

General Anxiety Disorder-Dormant Projects 39

General Anxiety Disorder-Discontinued Products 40

Appendix 41

Methodology 41

Coverage 41

Secondary Research 41

Primary Research 41

Expert Panel Validation 41

Contact Us 41

Disclaimer 42

List of Tables

Number of Products under Development for General Anxiety Disorder, H1 2015 7

Number of Products under Development for General Anxiety Disorder-Comparative Analysis, H1 2015 8

Number of Products under Development by Companies, H1 2015 9

Comparative Analysis by Late Stage Development, H1 2015 10

Comparative Analysis by Clinical Stage Development, H1 2015 11

Comparative Analysis by Early Stage Development, H1 2015 12

Comparative Analysis by Unknown Stage Development, H1 2015 13

Products under Development by Companies, H1 2015 14

General Anxiety Disorder-Pipeline by Edgemont Pharmaceuticals, LLC, H1 2015 15

General Anxiety Disorder-Pipeline by H. Lundbeck A/S, H1 2015 16

General Anxiety Disorder-Pipeline by Pfizer Inc., H1 2015 17

Assessment by Monotherapy Products, H1 2015 18

Number of Products by Stage and Target, H1 2015 20

Number of Products by Stage and Mechanism of Action, H1 2015 22

Number of Products by Stage and Route of Administration, H1 2015 23

Number of Products by Stage and Molecule Type, H1 2015 24

General Anxiety Disorder Therapeutics-Recent Pipeline Updates, H1 2015 35

General Anxiety Disorder-Dormant Projects, H1 2015 39

General Anxiety Disorder-Discontinued Products, H1 2015 40

List of Figures

Number of Products under Development for General Anxiety Disorder, H1 2015 7

Number of Products under Development for General Anxiety Disorder-Comparative Analysis, H1 2015 8

Number of Products under Development by Companies, H1 2015 9

Comparative Analysis by Clinical Stage Development, H1 2015 11

Assessment by Monotherapy Products, H1 2015 18

Number of Products by Top 10 Targets, H1 2015 19

Number of Products by Stage and Top 10 Targets, H1 2015 20

Number of Products by Top 10 Mechanism of Actions, H1 2015 21

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 22

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 23

Number of Products by Stage and Top 10 Molecule Types, H1 2015 24

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Edgemont Pharmaceuticals, LLC

H. Lundbeck A/S

Pfizer Inc.

General Anxiety Disorder Therapeutic Products under Development, Key Players in General Anxiety Disorder Therapeutics, General Anxiety Disorder Pipeline Overview, General Anxiety Disorder Pipeline, General Anxiety Disorder Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com